For the treatment of Covid-19 patients with remdesivir, poor renal- and liver function were both exclusion criteria in randomized clinical trials (RCTs) and contra-indication for treatment . Also, nephrotoxicity and hepatotoxicity are reported as adverse events . We retrospectively reviewed renal- and liver functions of covid-19 103 patients who received remdesivir in the 15 days after treatment initiation . Approximately 20% of the patient population met RCT exclusion criteria . In total , 11% of the patients had a decrease in estimated glomerular filtration rate larger than 10 ml/min/1.73m2 . Also , 25% and 35% had increased alanine transaminase and aspartate transaminase levels, respectively . However, serious adverse events were limited . Therefore, based on these preliminary results, contra-indications based on kidney- and liver function should not be absolute for remdesivir treatment in patients with Covid-19 if these functions are monitored regularly . A larger patient cohort is warranted to confirm our results.
Index: adverse events, covid-19, liver function, remdesivir, renal function